Unknown

Dataset Information

0

Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.


ABSTRACT: Antiangiogenic therapy is a promising new treatment modality for cancer, but it generally produces only transient tumor regression. We have previously devised a tumor-targeted nanosystem, in which a pentapeptide, CGKRK, delivers a proapoptotic peptide into the mitochondria of tumor blood vessel endothelial cells and tumor cells. The treatment was highly effective in glioblastoma mouse models completely refractory to other antiangiogenic treatments. Here, we identify p32/gC1qR/HABP, a mitochondrial protein that is also expressed at the cell surface of activated (angiogenic) endothelial cells and tumor cells, as a receptor for the CGKRK peptide. The results demonstrate the ability of p32 to cause internalization of a payload bound to p32 into the cytoplasm. We also show that nardilysin, a protease capable of cleaving CGKRK, plays a role in the internalization of a p32-bound payload. As p32 is overexpressed and surface displayed in breast cancers, we studied the efficacy of the nanosystem in this cancer. We show highly significant treatment results in an orthotopic model of breast cancer. The specificity of cell surface p32 for tumor-associated cells, its ability to carry payloads to mitochondria, and the efficacy of the system in important types of cancer make the nanosystem a promising candidate for further development.

SUBMITTER: Agemy L 

PROVIDER: S-EPMC3863797 | biostudies-other | 2013 Dec

REPOSITORIES: biostudies-other

altmetric image

Publications

Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.

Agemy Lilach L   Kotamraju Venkata R VR   Friedmann-Morvinski Dinorah D   Sharma Shweta S   Sugahara Kazuki N KN   Ruoslahti Erkki E  

Molecular therapy : the journal of the American Society of Gene Therapy 20130820 12


Antiangiogenic therapy is a promising new treatment modality for cancer, but it generally produces only transient tumor regression. We have previously devised a tumor-targeted nanosystem, in which a pentapeptide, CGKRK, delivers a proapoptotic peptide into the mitochondria of tumor blood vessel endothelial cells and tumor cells. The treatment was highly effective in glioblastoma mouse models completely refractory to other antiangiogenic treatments. Here, we identify p32/gC1qR/HABP, a mitochondri  ...[more]

Similar Datasets

| S-EPMC3198371 | biostudies-literature
| S-EPMC3578137 | biostudies-literature
| S-EPMC4955065 | biostudies-literature
| S-EPMC7501461 | biostudies-literature
| S-EPMC6085501 | biostudies-literature
| S-EPMC3679013 | biostudies-literature
| S-EPMC3609929 | biostudies-literature
| S-EPMC8480321 | biostudies-literature
| S-EPMC3530415 | biostudies-literature
| S-EPMC4437573 | biostudies-literature